{"name":"Shanghai Ming Ju Biotechnology Co., Ltd.","slug":"shanghai-ming-ju-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Relma-cel","genericName":"Relma-cel","slug":"relma-cel","indication":"Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)","status":"marketed"}]}],"pipeline":[{"name":"Relma-cel","genericName":"Relma-cel","slug":"relma-cel","phase":"marketed","mechanism":"Relma-cel is a CAR-T cell therapy that redirects patient T cells to recognize and eliminate cancer cells expressing a specific tumor antigen.","indications":["Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"PR Newswire","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOQkFaVndFQXV0M3lMRVJXejBwOUhlZjVTbGcwblU0ZEtfTEZNUGpTSktyMHZnWE1oWldXRmxoTnZGcmpGUW5PWjZmNzBUQnc1MGxPdnBaeGx4alBHZXZkN2RpSTBlc0lBOTZwYkdMNlRXWllTNXlJQXhqYkRfTVV1SUIxWVRiVE5FM0tKNU9aQnFVc19ncmFrS21SVnR5d05vbGJEZTdzaDJTbmRkV1B2NFphdGVmMUx2eTM0?oc=5","date":"2025-07-24","type":"pipeline","source":"News-Medical","summary":"How targeted therapies are reshaping autoimmune disease treatment - News-Medical","headline":"How targeted therapies are reshaping autoimmune disease treatment - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}